Anika Therapeutics (ANIK) Gross Margin (2010 - 2026)
Anika Therapeutics (ANIK) reported Gross Margin of 64.15% for Q1 2026, up 805.0% year-over-year from 7.09% in Q1 2025, and up 2.41% quarter-over-quarter from 62.65% in Q4 2025.
Anika Therapeutics (ANIK) Gross Margin (2010 - 2026) Analysis & Trends
Anika Therapeutics (ANIK) has 17 years of Gross Margin data on file, last reported at 64.15% in Q1 2026.
- Gross Margin for Q1 2026 came in at 64.15%, up 805.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 58.59% (down 266.0% YoY), and the FY2025 annual result was 56.56%, down 682.0% from the prior year.
- Gross Margin grew to 64.15% in Q1 2026 per ANIK's latest filing, from 62.65% in the prior quarter.
- Over five years, Gross Margin peaked at 66.69% in Q2 2024 and troughed at 199.14% in Q4 2023.
- A 5-year average of 33.73% and a median of 60.16% in 2023 frame the typical range for Gross Margin.
- The sharpest annual moves came in 2022 and 2024: Gross Margin sank 18607 bps in 2022, then surged 25510 bps in 2024.
- A 5-year view of Gross Margin shows it stood at 135.45% in 2022, then slumped by 47 bps to 199.14% in 2023, then jumped by 128 bps to 55.96% in 2024, then climbed by 12 bps to 62.65% in 2025, then advanced by 2 bps to 64.15% in 2026.
- Business Quant data shows ANIK's Gross Margin at 64.15% in Q1 2026, 62.65% in Q4 2025, and 56.02% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 49.52% |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 71.66% |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 82.93% |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 49.50% |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 98.31% |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 57.26% |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -293.83% |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 65.25% |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 61.20% |
| 10 | Anika Therapeutics | 197.89 Mn | 131.10 Mn | 19.00 Mn | 64.15% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 64.15% |
| Dec 31, 2025 | 62.65% |
| Sep 30, 2025 | 56.02% |
| Jun 30, 2025 | 50.90% |
| Mar 31, 2025 | 56.10% |
| Dec 31, 2024 | 55.96% |
| Sep 30, 2024 | 65.66% |
| Jun 30, 2024 | 66.69% |
| Mar 31, 2024 | 65.38% |
| Dec 31, 2023 | -199.14% |
| Sep 30, 2023 | 60.16% |
| Jun 30, 2023 | 65.40% |
| Mar 31, 2023 | 60.23% |
| Dec 31, 2022 | -135.45% |
| Sep 30, 2022 | 56.57% |
| Jun 30, 2022 | 62.69% |
| Mar 31, 2022 | 59.42% |
| Dec 31, 2021 | 50.62% |
| Sep 30, 2021 | 58.23% |
| Jun 30, 2021 | 54.56% |